Fiscal Year 2023 Second Quarter Highlights Net sales of $85.4 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $24.5 million increased 29.7% Med Device net sales of $60.9 million increased 2.6% Gross margin of 52.8% increased 100 basis points year over year GAAP loss per […]
Tag: AngioDynamics
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance
Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51.9% declined 20 basis points year over year GAAP loss per […]
AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance
Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022 […]
AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance
Fiscal 2022 Third Quarter Highlights Net sales of $74.0 million increased 3.9% compared to the prior-year quarter Med Tech grew 28.6% and Med Device declined 2.8% year over year Gross margin of 52.2% declined 190 basis points year over year GAAP loss per share of $0.13 and adjusted earnings per […]
AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance
Fiscal 2022 Second Quarter Highlights Net sales of $78.3 million increased 7.6% compared to the prior-year quarter Med Tech growth of 36.4% and Med Device growth of 0.8% year over year Gross margin of 51.8% declined 340 basis points year over year GAAP loss per share of $0.21, and adjusted […]
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
Fiscal 2022 First Quarter Highlights Net sales of $77.0 million increased 9.6% compared to the prior-year quarter Gross margin of 52.1% increased 120 basis points year over year GAAP loss per share of $0.18, and adjusted loss per share of $0.02 The Company commenced a Limited Market Release of its […]
AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results
Fiscal 2021 Fourth Quarter Highlights Net sales of $76.8 million increased 31.7% compared to the prior-year quarter Gross margin of 55.1% increased 330 basis points year over year GAAP loss per share of $0.51, inclusive of a $14.0 million write-off of OARTrac intangible assets, and adjusted earnings per share of […]
AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System
Thrombectomy Device with Off-Circuit Mechanical Aspiration Design for Treatment of Undesirable Intravascular Material in Venous System and Peripheral Vasculature LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it […]
AngioDynamics Appoints Richard C. Rosenzweig Senior Vice President, General Counsel and Secretary, Promotes Juan Carlos Serna to Senior Vice President, Scientific & Clinical Affairs
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Richard C. Rosenzweig as Senior Vice President, General Counsel, effective January 31, 2021. Mr. Rosenzweig will also serve as Corporate Secretary […]
AngioDynamics Announces Presentation of Positive Safety, Efficacy Results from RAPID Outcomes Database
Represents Largest Catheter Based Thromboaspiration Study Completed to Date LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the safety and efficacy results from the Registry of AngioVac* System Procedures In Detail (RAPID) database. Results […]
Recent
Dr. Curtis Langlotz Joins Sirona Medical’s Board
4C Medical Secures $175M Series D Preferred Stock Financing
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Popular
- No commented posts yet